Loading clinical trials...
Loading clinical trials...
The Role of microRNA-210 in Regulating Oxidative Stress in Patients With Peripheral Artery Disease
MicroRNA-210 (miR-210) can be a potential therapeutic target of patients with peripheral artery disease (PAD). Recent evidence suggests the role of miR-210 and oxidative stress in the pathophysiology of PAD and its association with mitochondrial function, oxidative metabolism, walking distances and quality of life. The protocol evaluates the mechanisms which miR-210 regulates oxidative stress and provides evidence of potential therapeutic strategies.
The investigators will randomize 180 PAD patients that undergoing a revascularization operation in two groups: (1) an endovascular procedure or (2) an open bypass procedure. They are also planning to recruit 50 non-PAD healthy control subjects. The goal is to answer the main hypothesis that miR-210 gene expression is a master regulator of oxidative stress and is associated with mitochondrial dysfunction, oxidative metabolism, walking function and quality of life.
Age
30 - No limit years
Sex
ALL
Healthy Volunteers
Yes
UT Austing Dell Medical School
Austin, Texas, United States
Baylor Scott and White
Temple, Texas, United States
Start Date
September 15, 2019
Primary Completion Date
August 29, 2024
Completion Date
August 25, 2025
Last Updated
February 23, 2026
230
ACTUAL participants
Revascularization operation
PROCEDURE
Control group
OTHER
Lead Sponsor
University of West Florida
Collaborators
NCT07472049
NCT07161583
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07322913